MORRISTOWN, N.J.--()--RSA, the leading global Life Sciences Executive Search and Interim Management specialist, is pleased to announce the placement of Jack Talley as President and Chief Executive Officer of Actinium Pharmaceuticals, Inc.
“We are very pleased to have Jack Talley on board as our new CEO. RSA did an outstanding job and we would like to thank them for their professional approach in delivering a truly excellent result.”
The placement of pharmaceutical industry veteran Jack Talley successfully concludes RSA’s Executive Search. Hired by Actinium, RSA was tasked with finding a seasoned executive to strengthen its senior management team as the company prepares to raise additional capital and list on the public stock markets later this year.
A private biopharmaceutical company, Actinium develops innovative targeted radio-immunotherapeutics to treat various cancers. With more than 30 years of experience in marketing, drug development and regulatory matters, Jack proved the perfect candidate at this pivotal moment in the Company’s history.
Shawn O’Connor, President of RSA Americas says “We are delighted to conclude our search with the placement of such an exceptional candidate. Previously the CEO of EpiCept Corporation, Jack has immense experience in the industry and we believe he is well positioned to succeed in his new role.”
Sandesh Seth, a Board Member of Actinium says “We are very pleased to have Jack Talley on board as our new CEO. RSA did an outstanding job and we would like to thank them for their professional approach in delivering a truly excellent result.”
RSA is a global leader in Executive Search and Interim Management to the Life Sciences sectors with offices in China, Germany, Singapore, Switzerland, UK, Turkey and USA. To find out more go to www.theRSAgroup.com.